adnexa

(redirected from adnexus)
Also found in: Thesaurus, Medical, Encyclopedia.

ad·nex·a

 (ăd-nĕk′sə)
pl.n.
Accessory or adjoining anatomical parts, as ovaries and fallopian tubes in relation to the uterus.

[Latin, neuter pl. of adnexus, past participle of adnectere, to bind to; see annex.]

ad·nex′al adj.

adnexa

(ædˈnɛksə)
pl n
(Anatomy) anatomy adjoining organs, esp of the uterus
[C19: New Latin: appendages]
adˈnexal adj

ad•nex•a

(ædˈnɛk sə)

n.pl.
appended or accessory anatomical parts, as the eyelids in relation to the eyes.
[1895–1900; < Latin, neuter pl. of adnexus physically attached, joined, past participle of adnectere to attach; see ad-, nexus]
ad•nex′al, adj.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.adnexa - accessory or adjoining anatomical parts or appendages to an organ (especially of the embryo)adnexa - accessory or adjoining anatomical parts or appendages to an organ (especially of the embryo); "Fallopian tubes and ovaries are adnexa of the uterus"
body part - any part of an organism such as an organ or extremity
Translations

ad·nex·a

n., pl. anejos, anexos, apéndices tales como las trompas de Falopio.
References in periodicals archive ?
Prior to Avila, Katrine was Vice President Business Development at Adnexus Therapeutics, a company developing a new class of protein therapeutics.
Previously, she was vice president Business Development at Adnexus Therapeutics.
Some of the larger acquisitions of mAb producers by pharmaceutical companies this year were Bristol-Myers Squibb's purchase of Adnexus for $415 million in September and Roche's $56.
In an effort to expand its cancer treatments, Bristol-Myers is acquiring developers of experimental medicines, such as Adnexus Therapeutics Inc.
Bristol-Myers Squibb Company (Princeton, NJ) and Adnexus Therapeutics announced the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire privately held Adnexus Therapeutics, developer of a new therapeutic class of biologics called Adnectins.
of New York agreed to buy closely held Adnexus Therapeutics of Waltham for $430 million to gain an experimental cancer medicine.
With a primary focus on technology, healthcare, and energy, portfolio companies have included Adify, Adnexus Therapeutics, Apple Computer, Athenahealth, Centocor, Check Point Software, DoubleClick, Gilead Sciences, Idec Pharmaceuticals, Illumina, Intel, Millennium Pharmaceuticals, Sirna Therapeutics, StrataCom, and Vostu.